Hims & Hers (HIMS) stock rose 5% on October 28, the day HHS issued an interim policy on compounding six peptides. Hims has also opened an RSVP waitlist for a line called Peptides+, and you cannot buy anything on it yet. The HHS policy is a temporary enforcement position, not an FDA approval.
Disclosure: links to Hims pages go to the company’s own website.
Why did HIMS stock rise on October 28?
Hims & Hers shares rose 5% that day, according to a Yahoo Finance report on the 5% move. TIME also reported the 5% rise and called the decision a boon for companies like Hims & Hers.
The move followed an HHS interim peptide policy. HHS says it will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy only applies when these conditions are met:
- The bulk ingredient comes from an FDA-registered manufacturer and has a valid certificate of analysis.
- The compounded drug is made from a patient-specific prescription.
- The product contains a single ingredient from the list.
- Serious adverse events and quality problems are reported to FDA’s MedWatch program.
- The label reads: “This is a compounded drug product. Not for resale.”
HHS also says it may revisit the policy if a safety signal or product quality issue arises.
Hims’s chief medical officer, Dr. Anant Vinjamoori, pointed to the company’s “very own US-based peptide manufacturing facility” and its dosing protocols. CEO Andrew Dudum called the news “encouraging progress.” Both quotes come from the Yahoo Finance report.
Will HIMS offer peptides?
Hims has a Hims Peptides+ page titled “Coming Soon.” The only action on it is an RSVP to join a waitlist. The page says the compounded treatments are “not FDA approved and have not been evaluated by the FDA for safety, effectiveness, or quality.”
The page shows seven products, each with a label from Hims:
| Product on the Peptides+ page | Hims’s label | Named in HHS’s Oct 28 interim policy? |
|---|---|---|
| Sermorelin | Peptide | No |
| NAD+ | Coenzyme | No |
| TB-500 | Peptide | Yes |
| L-carnitine | Amino acid derivative | No |
| Glutathione | Peptide | No |
| Vitamin B12 | Vitamin | No |
| BPC-157 | Peptide | Yes |
The page’s description names only five of these products. BPC-157 and TB-500 appear in the product grid but not in the description.
Hims says its treatments are built on active ingredients from FDA-registered facilities, clinically guided protocols, licensed providers, US-licensed pharmacies and ready-to-inject vials “tested for purity and potency.” These are company claims, not independently verified. The protocols are credited to three doctors: Dr. Anant Vinjamoori, Dr. Jessica Shepherd and Dr. Mike Bohl.
In August, CEO Andrew Dudum told investors that Hims would sell peptides already legal for manufacturing, including NAD+, sermorelin and glutathione, by the end of the year, according to a Reuters report from August 12. Reuters also reported that Hims had begun stability and validation testing on BPC-157, and that Dudum was waiting for “full and final rulemaking” from the FDA before selling the peptides still under review.
The Peptides+ page does not list a price, a launch date, doses or states. Check that page or the RSVP form for updates before you plan around a start date.
Is HIMS still a good stock?
This article will not call HIMS a buy or a sell. Here are the facts that were reported.
- The October 28 move: up 5% that day, per the Yahoo Finance report.
- Year to date: the Stocktwits report carried by Yahoo Finance said HIMS was down 8% year to date on October 28.
- Analyst view in August: Reuters quoted Cedar Grove Capital’s Paul Cerro and Morningstar’s Keonhee Kim, who said the peptide offering was unlikely to drive revenue growth in 2026. They also said grey-market sales make NAD+ demand hard to quantify.
- Market size: Reuters reported that analysts put peptides at a $2.2 billion to $3.3 billion market.
- FTC lawsuit: the Federal Trade Commission filed a lawsuit in late July. It alleges deceptive privacy practices and misleading billing or cancellation practices. These are allegations, not findings.
For a current price, check a live quote on a finance site or your brokerage app. For analyst ratings and company filings, the investor relations section of the company’s own site is the place to start. If someone is pitching you a stock pick, a checklist for paid investment newsletters covers what to ask. For one paid example, see motley fool stock advisor worth it. More market news is in Business Finance and Industry Markets, and for the broader market picture, see updated stock market shatters all-time records.
What do supporters and critics say about peptides?
The American Academy of Peptide Medicine, a supporter quoted by TIME, says the policy moves patients away from gray and black markets.
Critics include the group Americans for Safe and Effective Medicines, which said “American consumers should not be treated like guinea pigs.” TIME also quoted Georgetown pharmacologist Dr. Adriane Fugh-Berman, who called the peptides “untested and poorly characterized experimental drugs.” Wolters Kluwer pharmacist Annie Lambert warned that pharmacies rushing to supply telehealth sites may cut corners on sourcing, facilities, training and sterility testing.
TIME reported that, shortly after the notice, telehealth websites were marketing the six peptides at $199 to $249 a month. Those are not Hims prices. TIME’s report is dated October 28, 2026.
What should you know before buying a peptide?
HHS states that “compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” Read the FDA’s list of risky bulk substances for each peptide you are considering. FDA placed these peptides on its significant-safety-risk (Category 2) list in 2023; HHS says they left it on April 22, 2026. FDA’s page, current as of April 22, 2026, describes the concerns it had. For BPC-157, FDA says it “has identified no, or only limited, safety-related information for the proposed routes of administration.” For TB-500, FDA says it “has not identified any human exposure data” on drug products containing that fragment. For what human trials have covered, read the peptides human studies (our research library) guide.
The real path to any of these is a licensed prescriber and a pharmacy that compounds under the rules above. Bring these questions to both:
- Is the pharmacy state-licensed, and does it compound under section 503A?
- Who makes the bulk ingredient, is that manufacturer FDA-registered, and can I see the certificate of analysis for my batch?
- Is the prescription written for me, and is the product a single ingredient?
- Does the label include “This is a compounded drug product. Not for resale.”?
- Who reports side effects, and how?
- What is the full monthly cost, and how do I cancel? Ask for the answer in writing.
Before you order
- Check the Peptides+ page for prices, a launch date, doses and states before planning a start.
- Read the cancellation and billing terms at checkout before you give any card details.
- Ask your prescriber which product, if any, fits your situation.
- Ask the pharmacy for the certificate of analysis for each batch.
By USPatriotNews.com Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
